Cervical Cancer, MRI, Prognostic Model, Radiotherapy
Conditions
Brief summary
This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.
Detailed description
Even with the development of advanced technology, the prognosis for CC patients who received radiotherapy is still an intractable problem. Almost 40% suffered disease recurrence among locally advanced patients after radiotherapy and the reported 5-year overall survival is 50-70%. The present FIGO staging is controversial in pre-treatment assessment, which is mainly based on physical examination. An ambiguous diagnosis leads to different treatment strategies and follow-up plans, which is associated with prognosis non-improvement. Incorporation of the tumor involvement features based on the MRI into pre-treatment assessment could standardize and improve the consistency and repeatability of diagnosis.
Interventions
RADIATIONTreatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
Sponsors
Fujian Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* (1) pathologically confirmed CC, (2) initially treated in our center
Exclusion criteria
* (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 1-36 months | the interval from diagnostic day to death or the last follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival | 1-36 months | the interval from diagnostic day to death, the last follow-up, or the onset of regional recurrence or distant metastasis |
Countries
China
Contacts
Primary ContactYang Sun
Outcome results
None listed